New FDA warning for Tysabri
April 28, 2010…the newsletter with Continue…
…the newsletter with Continue…
View commentary by Daniel Selchen, MD Following news reports last fall of a possible cure for MS, clinicians and MS Societies worldwide have been inundated with inquiries about the new procedure. Its originator, Dr. Paulo Zamboni of Ferrara, Italy, has reported that a condition that he calls chronic cerebrospinal venous insufficiency (CCSVI) is the underlying problem in multiple sclerosis. Subscribe to read more It takes 30 seconds or login using…
A group in the U.K. has published a consensus statement on the use of the atypical antipsychotic aripiprazole for acute mania (Aitchison et al. J Psychopharmacol 2009; 23: 231-240). Unlike other atypical antipsychotic agents (clozapine, risperidone, olanzapine, quetiapine, ziprasidone), aripiprazole acts as a partial agonist at the dopamine D2 and serotonin 5HT-1A and 5HT-2C receptors, and as a 5HT-2A antagonist (for a recent review see Pae CU. E…
…Milnacipran is a dual serotonin-norepinephrine reuptake inhibitor (SNRI) in use in Europe, Asia and Australia. Its norepineprine:serotonin effects are 3:1, in contrast to other SNRIs (e.g. venlafaxine, with a 1:30 norepineprine:serotonin ratio). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…A longitudinal study has examined cognitive decline in 106 patients with early Parkinsons disease (mean age 61.2 years). Cognitive decline was assessed using the Mini Mental State Examination (MMSE; mean baseline 27.8) (Kandiah et al. Mov Disord 2009); epublished February 3, 2009. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…